Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Diabetes Metab J > Volume 46(4); 2022 > Article
Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
Eugene Hanorcid
Diabetes & Metabolism Journal 2022;46(4):564-566.
Published online: July 27, 2022
  • 134 Download

Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea

Corresponding author: Eugene Han orcid Division of Endocrinology and Metabolism, Department of Internal Medicine, Keimyung University School of Medicine, 1095 Dalgubeol-daero, Dalseo-gu, Daegu 42601, Korea E-mail:

Copyright © 2022 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease; globally, a quarter of the general population is affected [1]. In recent decades, the increasing prevalence of NAFLD has been linked to the alarming increase in obesity, insulin resistance, and type 2 diabetes mellitus (T2DM), which are risk factors for both NAFLD and chronic kidney disease (CKD). The main etiologies of chronic liver disease in Korea have shown a decreasing trend of hepatitis B infection and an increasing trend of NAFLD [2,3]. NAFLD comprises a broad spectrum of liver diseases ranging from simple steatosis (non-alcoholic fatty liver [NAFL]) and non-alcoholic steatohepatitis (NASH) to liver fibrosis and liver cirrhosis. Unlike NAFL, which has a relatively favorable outcome when unaccompanied by metabolic impairment, NASH involves hepatocyte injury and inflammation; therefore, NASH is regarded as an early stage in the progression to hepatic fibrosis or cirrhosis [4].
Among multiple organs affected by NAFLD, the kidney is the major counterpart which shares denominator underlying metabolic impartments with liver disease. NAFLD involves a scope of kidney dysfunctions from albuminuria to CKD. The epidemiological evidence suggests that NAFLD is an in dependent risk factor for albuminuria, and the severity of steatosis is correlated with albuminuria prevalence [5,6]. Moreover, advanced liver fibrosis is associated with proteinuria and increased urinary markers regardless of albuminuria presence [7,8]. In the literature, several cross-sectional studies found that the prevalence of CKD (defined as estimated glomerular filtration rate [eGFR] less than 60 mL/min/1.73 m2) was much greater in patients with biopsy-proven NAFLD/NASH than in those without NAFLD or NASH [9,10]. Although these findings were consistent after adjusting confounding factors, it is still difficult to distinguish a clear causal relationship between NAFLD and CKD when those diseases co-exist and share common risk factors. Additionally, the original definition of CKD, abnormalities in kidney function or structure that persist over 3 months, is hard to confirm in cross-sectional design. Few longitudinal studies on NAFLD and incident CKD have been conducted, especially in a population with T2DM.
In this issue of the Diabetes and Metabolism Journal, Seo et al. [11] demonstrated a causal relationship of NAFLD assessed by ultrasound and advanced liver fibrosis in CKD incidence in a longitudinal cohort study. Over a mean follow-up period of 8.3 years, patients with advanced liver fibrosis had a higher risk of incident of CKD compared to those without advanced liver fibrosis (hazard ratio, 1.59 to 1.75; all P<0.05). Interestingly, an increased CKD incidence was not observed when dividing by NAFLD presence. This finding was similar the results of Jang et al. [12], who showed that the severity of NAFLD was associated with a decline in annual eGFR change, and an annual eGFR change in NAFLD was not observed in subgroup analysis in patients with T2DM. Another Korean study demonstrated that the increased incidence of CKD in NAFLD did not indicate a direct association between NAFLD and CKD in diabetes subgroup analysis [13]. Compared to previous Italian longitudinal studies of NAFLD in populations with diabetes, which concluded that NAFLD increased the risk of incident CKD [14,15], the current study population had a relatively short duration of diabetes (mean duration of diabetes 7.4 years vs. 11 to 18 years in Italian studies). Of note, Asian patients with diabetes are more susceptible to kidney complications than their Caucasian counterparts [16]. As the authors stated, the longer follow-up duration of the current study (8.3 years vs. 5.2 to 6.5 years in Italian studies) might have influenced the discrepancy.
The longitudinal study by Seo et al. [11] provided additional information supporting that T2DM patients with severe forms of NAFLD are more likely to progress to CKD, which is a strong predictor for cardiovascular events and overall mortality. This study has contributed to our understanding of NAFLD in Asian populations with diabetes. Although further investigations are needed to determine the direct effect of NAFLD on CKD, and on crosstalk between the liver and kidneys, it is important for healthcare providers to consider NAFLD as a potential indicator for high risk of CKD. Comprehensive approaches including NAFLD assessment are needed to manage patients with diabetes.


No potential conflict of interest relevant to this article was reported.

  • 1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.ArticlePubMed
  • 2. Song BG, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, et al. Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. Korean J Intern Med 2022 May 13 [Epub]. .Article
  • 3. Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, et al. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017. Clin Mol Hepatol 2020;26:209-15.ArticlePubMedPMCPDF
  • 4. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609.ArticlePubMed
  • 5. Han E, Kim MK, Jang BK, Kim HS. Albuminuria is associated with steatosis burden in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab J 2021;45:698-707.ArticlePubMedPMCPDF
  • 6. Wijarnpreecha K, Thongprayoon C, Boonpheng B, Panjawatanan P, Sharma K, Ungprasert P, et al. Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018;30:986-94.ArticlePubMed
  • 7. Han E, Cho Y, Kim KW, Lee YH, Kang ES, Cha BS, et al. Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. Medicine (Baltimore) 2020;99:e21038.ArticlePubMedPMC
  • 8. Han E, Kim MK, Lee YH, Kim HS, Lee BW. Association between nonalbumin proteinuria and renal tubular damage of N-acetyl-β-d-glucosaminidase and its clinical relevance in patients with type 2 diabetes without albuminuria. J Diabetes Complications 2019;33:255-60.ArticlePubMed
  • 9. Yasui K, Sumida Y, Mori Y, Mitsuyoshi H, Minami M, Itoh Y, et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2011;60:735-9.ArticlePubMed
  • 10. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010;5:2166-71.ArticlePubMedPMC
  • 11. Seo DH, Suh YJ, Cho Y, Ahn SH, Seo S, Hong S, et al. Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab J 2022;46:630-9.ArticlePubMedPMCPDF
  • 12. Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep 2018;8:4718.ArticlePubMedPMCPDF
  • 13. Sinn DH, Kang D, Jang HR, Gu S, Cho SJ, Paik SW, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study. J Hepatol 2017;67:1274-80.ArticlePubMed
  • 14. Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care 2014;37:1729-36.ArticlePubMedPDF
  • 15. Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008;19:1564-70.ArticlePubMedPMC
  • 16. Young BA, Katon WJ, Von Korff M, Simon GE, Lin EH, Ciechanowski PS, et al. Racial and ethnic differences in microalbuminuria prevalence in a diabetes population: the pathways study. J Am Soc Nephrol 2005;16:219-28.PubMed

Figure & Data



    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite this Article
        Cite this Article
        export Copy Download
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        • Citation for the content below
        Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
        Diabetes Metab J. 2022;46(4):564-566.   Published online July 27, 2022
      • XML DownloadXML Download
      Related articles
      Han E. Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease. Diabetes Metab J. 2022;46(4):564-566.

      Diabetes Metab J : Diabetes & Metabolism Journal
      Close layer